Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.56 |
| ▸ | SRC | P12931 | 8/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054175 | 0.82 | SRC (0.60) | EGFRERBB2SRCGAKMAP2K1 | |
| Bromide SCHEMBL31554527 | 0.81 | HSPB1 (0.42) | EGFRERBB2PDGFRBPDGFRAABCG2 | |
| SCHEMBL31554431 | 0.80 | S1PR4 (0.46) | EGFRERBB2PDGFRBPDGFRAABCG2 | |
| SCHEMBL31554554 | 0.80 | HSPB1 (0.42) | EGFRERBB2PDGFRBPDGFRAABCG2 | |
| SCHEMBL31554417 | 0.78 | MEN1 (0.46) | PDGFRBPDGFRAABCG2 | |
| SCHEMBL18548554 | 0.78 | TRPA1 (0.68) | EGFRABCG2 | |
| SCHEMBL29487188 | 0.78 | PDGFRA (0.59) | SRCPDGFRBPDGFRA | |
| SCHEMBL174159 | 0.78 | PDGFRA (0.59) | SRCPDGFRBPDGFRA | |
| SCHEMBL31554441 | 0.76 | PDGFRB (0.45) | EGFRERBB2PDGFRBPDGFRA | |
| SCHEMBL22009936 | 0.73 | PDGFRA (0.56) | SRCPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | EGFR 6/4885ERBB2 2/4885SRC 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.